Completed PHASE2 INTERVENTIONAL 4-arm NCT02390050

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus

Sponsor: Theracos

Conditions Diabetes Mellitus, Type 2

Interventions Bexagliflozin tablets Bexagliflozin tablets, placebo

Updated 13 times since 2017 Last updated: Jun 11, 2021 Started: May 12, 2015 Primary completion: Jun 3, 2016 Completion: Jun 3, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Theracos and has accumulated 13 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 8 earlier versions

Sep 2021 — Dec 2022 [monthly]

Completed PHASE2
May 2021 — Sep 2021 [monthly]

Completed PHASE2
Jan 2021 — May 2021 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Sep 2019 — Nov 2019 [monthly]

Completed PHASE2

Phase: PHASE2_PHASE3 → PHASE2
Jun 2018 — Sep 2019 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theracos

Data source: Theracos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Calabash, United States , Canoga Park, United States , Chino, United States , Cincinnati, United States , DeSoto, United States , Endwell, United States , Fort Lauderdale, United States , Fort Worth, United States , Hachioji-shi, Japan and 39 more locations